α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

The potential use of radionuclides in therapy has been recognized for many decades. A
number of radionuclides, such as iodine-131 (131 I), phosphorous-32 (32 P), strontium-90 …

This article presents a general discussion on what has been achieved so far and on the
possible future developments of targeted alpha (α)-particle therapy (TAT). Clinical …

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy
that specifically uses radiolabeled peptides as biological targeting vectors designed to …

Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation
to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional …

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Chlorotoxin-conjugated multifunctional dendrimers labeled with radionuclide 131I were
synthesized and utilized for targeted single photon emission computed tomography …

Because of the broad incidence, morbidity and mortality associated with prostate-derived
cancer, the development of more effective new technologies continues to be an important …

Background With recent advances in novel approaches to cancer therapy and imaging, the
application of theranostic techniques in personalised medicine has emerged as a very …